These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. Plevy S; Silverberg MS; Lockton S; Stockfisch T; Croner L; Stachelski J; Brown M; Triggs C; Chuang E; Princen F; Singh S Inflamm Bowel Dis; 2013 May; 19(6):1139-48. PubMed ID: 23518807 [TBL] [Abstract][Full Text] [Related]
48. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Xu Y; Xu F; Li W; Li M; Dong S; Zhang Y; Norman GL; Zhao Q; Liu L Scand J Gastroenterol; 2020 Jul; 55(7):806-813. PubMed ID: 32568566 [No Abstract] [Full Text] [Related]
49. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Linskens RK; Mallant-Hent RC; Groothuismink ZM; Bakker-Jonges LE; van de Merwe JP; Hooijkaas H; von Blomberg BM; Meuwissen SG Eur J Gastroenterol Hepatol; 2002 Sep; 14(9):1013-8. PubMed ID: 12352222 [TBL] [Abstract][Full Text] [Related]
50. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Smids C; Horjus Talabur Horje CS; Groenen MJM; van Koolwijk EHM; Wahab PJ; van Lochem EG Scand J Gastroenterol; 2017 Oct; 52(10):1104-1112. PubMed ID: 28661185 [TBL] [Abstract][Full Text] [Related]
51. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Lawrance IC; Hall A; Leong R; Pearce C; Murray K Inflamm Bowel Dis; 2005 Oct; 11(10):890-7. PubMed ID: 16189418 [TBL] [Abstract][Full Text] [Related]
53. Serological markers facilitate the diagnosis of Crohn's disease. Gao X; Zhang Y Postgrad Med; 2021 Apr; 133(3):286-290. PubMed ID: 33406965 [No Abstract] [Full Text] [Related]
54. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Solberg IC; Lygren I; Cvancarova M; Jahnsen J; Stray N; Sauar J; Schreiber S; Moum B; Vatn MH; Inflamm Bowel Dis; 2009 Mar; 15(3):406-14. PubMed ID: 19009607 [TBL] [Abstract][Full Text] [Related]
55. Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study. Kristensen VA; Cvancarova M; Høivik ML; Moum B; Vatn MH Scand J Gastroenterol; 2020 Apr; 55(4):436-441. PubMed ID: 32252542 [No Abstract] [Full Text] [Related]
56. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. Sura SP; Ahmed A; Cheifetz AS; Moss AC J Clin Gastroenterol; 2014 Apr; 48(4):351-5. PubMed ID: 24492405 [TBL] [Abstract][Full Text] [Related]
57. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Bansi DS; Chapman RW; Fleming KA Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455 [TBL] [Abstract][Full Text] [Related]
58. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Pang Y; Ruan H; Wu D; Lang Y; Sun K; Xu C Allergy Asthma Clin Immunol; 2020; 16():37. PubMed ID: 32477415 [TBL] [Abstract][Full Text] [Related]